What Have Mass Spectrometry-Based Proteomics and Metabolomics (Not) Taught Us about Psychiatric Disorders?
Complex Psychiatry · 2015
DOI: 10.1159/000381902 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Complex Psychiatry, 2015. Verfasst von Christoph W Turck und 1 weiteren Autor:innen. Beteiligte Einrichtung: Max Planck Institute of Psychiatry, Munich, Germany. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Understanding the molecular causes and finding appropriate therapies for psychiatric disorders are challenging tasks for research; -omics technologies are used to elucidate the molecular mechanisms underlying brain dysfunction in a hypothesis-free manner. In this review, we will focus on mass spectrometry-based proteomics and metabolomics and address how these approaches have contributed to our understanding of psychiatric disorders. Specifically, we will discuss what we have learned from mass spectrometry-based proteomics and metabolomics studies in rodent models and human cohorts, outline current limitations and discuss the potential of these methods for future applications in psychiatry.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Max Planck Institute of Psychiatry, Munich, Germany.
Zitieren
APA
Turck, C. W., & Filiou, M. D. (2015). What Have Mass Spectrometry-Based Proteomics and Metabolomics (Not) Taught Us about Psychiatric Disorders?. Complex Psychiatry. https://doi.org/10.1159/000381902
Vancouver
Turck CW, Filiou MD. What Have Mass Spectrometry-Based Proteomics and Metabolomics (Not) Taught Us about Psychiatric Disorders?. Complex Psychiatry. 2015. doi:10.1159/000381902
BibTeX
@article{Turck2015,
author = {Turck, Christoph W and Filiou, Michaela D},
title = {What Have Mass Spectrometry-Based Proteomics and Metabolomics (Not) Taught Us about Psychiatric Disorders?},
journal = {Complex Psychiatry},
year = {2015},
doi = {10.1159/000381902}
}
EUVIMED